| Identification | More | [Name]
Cefoselis sulfate | [CAS]
122841-12-7 | [Synonyms]
CEFOSELIS SULFATE
FK 037
(6R-(6alpha,7beta(Z)))-7-(((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl)methyl)-8-oxo-5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid sulfate
Winsef | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C19H24N8O10S3 | [MDL Number]
MFCD00864819 | [Molecular Weight]
620.64 | [MOL File]
122841-12-7.mol |
| Chemical Properties | Back Directory | [storage temp. ]
4°C, protect from light, stored under nitrogen | [solubility ]
DMSO : 100 mg/mL (161.12 mM; Need ultrasonic)H2O : 14.29 mg/mL (23.02 mM; Need ultrasonic) | [form ]
Powder | [color ]
White to off-white | [InChIKey]
LZOLCSVRFKCSEM-GZRJWVSENA-N | [SMILES]
S(O)(O)(=O)=O.C(C1=C(CS[C@]2([H])[C@H](NC(=O)/C(/C3=CSC(N)=N3)=N\OC)C(=O)N12)CN1C=CC(=N)N1CCO)(=O)O |&1:10,12,r| | [CAS DataBase Reference]
122841-12-7(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Cefoselis is a new fourth-generation cephalosporin and was launched
in Japan as a parenteral antibiotic for a variety of infections including
Staphylococcus aureus (particularly the methicillin-resistant MRSA) and
Pseudornonas aeruginosa. It can be prepared in 3 related ways, all using 2-
pyrazolomethyl-3-cephem-4-carboxylic as the key intermediate. In preclinical
studies, Cefolesis had better MIC50s than Ceftazidime against Streptococcus
pneurnoniae or Staphflococcus aureus (methicillin-sensitive MSSA or resistant
MRSA) and showed significant antibacterial activity against Citrobacter and
Enterobacter.
Cefolesis is well tolerated in clinical studies, being eliminated mainly via
glomerular filtration in humans. | [Originator]
Fujisawa (Japan) | [Uses]
antibiotic | [Definition]
ChEBI: Cefoselis sulfate is an azaheterocycle sulfate salt. It is functionally related to a member of cefoselis. | [Brand name]
Wincef | [References]
[1] K OHTAKI. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release.[J]. Journal of Neural Transmission, 2004, 111 12: 1523-1535. DOI:10.1007/s00702-004-0177-0.
[2] PRZEMYSŁAW ZALEWSKI Anna J Judyta Cielecka Piontek. Stability of cefoselis sulfate in aqueous solutions[J]. Reaction Kinetics, Mechanisms and Catalysis, 2012, 108 2: 285-292. DOI:10.1007/s11144-012-0523-4.
[3] ZHU, D., et al., In vitro activities of cefoselis compared to β-lactams and other antibacterial agents aganst gram-positive and gram-negative clinical isolates. Chinese Journal of Infection and Chemotherapy, 2011. 4: p. 002.
[4] ANNA KING Ian P Linda Bethune. The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin[J]. Clinical Microbiology and Infection, 1995, 1 1: Pages 13-17. DOI:10.1111/j.1469-0691.1995.tb00018.x. |
|
|